CD38 and chronic lymphocytic leukemia

A decade later

Fabio Malavasi, Silvia Deaglio, Rajendra Damle, Giovanna Cutrona, Manlio Ferrarini, Nicholas Chiorazzi

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

This review highlights a decade of investigations into the role of CD38 in CLL. CD38 is accepted as a dependable marker of unfavorable prognosis and as an indicator of activation and proliferation of cells when tested. Leukemic clones with higher numbers of CD38 + cells are more responsive to BCR signaling and are characterized by enhanced migration. In vitro activation through CD38 drives CLL proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2. Finally, CD38 is under a polymorphic transcriptional control after external signals. Consequently, CD38 appears to be a global molecular bridge to the environment, promoting survival/proliferation over apoptosis. Together, this evidence contributes to the current view of CLL as a chronic disease in which the host's microenvironment promotes leukemic cell growth and also controls the sequential acquisition and accumulation of genetic alterations. This view relies on the existence of a set of surface molecules, including CD38, which support proliferation and survival of B cells on their way to and after neoplastic transformation. The second decade of studies on CD38 in CLL will tell if the molecule is an effective target for antibody-mediated therapy in this currently incurable leukemia.

Original languageEnglish
Pages (from-to)3470-3478
Number of pages9
JournalBlood
Volume118
Issue number13
DOIs
Publication statusPublished - Sep 29 2011

Fingerprint

Chemotaxis
B-Cell Chronic Lymphocytic Leukemia
Leukemia
B-Lymphocytes
Chronic Disease
Clone Cells
Cell Count
Chemical activation
Cell Proliferation
Apoptosis
Molecules
Antibodies
Cell growth
Growth
Cells
Therapeutics
In Vitro Techniques
Drive

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Malavasi, F., Deaglio, S., Damle, R., Cutrona, G., Ferrarini, M., & Chiorazzi, N. (2011). CD38 and chronic lymphocytic leukemia: A decade later. Blood, 118(13), 3470-3478. https://doi.org/10.1182/blood-2011-06-275610

CD38 and chronic lymphocytic leukemia : A decade later. / Malavasi, Fabio; Deaglio, Silvia; Damle, Rajendra; Cutrona, Giovanna; Ferrarini, Manlio; Chiorazzi, Nicholas.

In: Blood, Vol. 118, No. 13, 29.09.2011, p. 3470-3478.

Research output: Contribution to journalArticle

Malavasi, F, Deaglio, S, Damle, R, Cutrona, G, Ferrarini, M & Chiorazzi, N 2011, 'CD38 and chronic lymphocytic leukemia: A decade later', Blood, vol. 118, no. 13, pp. 3470-3478. https://doi.org/10.1182/blood-2011-06-275610
Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: A decade later. Blood. 2011 Sep 29;118(13):3470-3478. https://doi.org/10.1182/blood-2011-06-275610
Malavasi, Fabio ; Deaglio, Silvia ; Damle, Rajendra ; Cutrona, Giovanna ; Ferrarini, Manlio ; Chiorazzi, Nicholas. / CD38 and chronic lymphocytic leukemia : A decade later. In: Blood. 2011 ; Vol. 118, No. 13. pp. 3470-3478.
@article{2d5f5a425ed145f2b6f64cb6373365b4,
title = "CD38 and chronic lymphocytic leukemia: A decade later",
abstract = "This review highlights a decade of investigations into the role of CD38 in CLL. CD38 is accepted as a dependable marker of unfavorable prognosis and as an indicator of activation and proliferation of cells when tested. Leukemic clones with higher numbers of CD38 + cells are more responsive to BCR signaling and are characterized by enhanced migration. In vitro activation through CD38 drives CLL proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2. Finally, CD38 is under a polymorphic transcriptional control after external signals. Consequently, CD38 appears to be a global molecular bridge to the environment, promoting survival/proliferation over apoptosis. Together, this evidence contributes to the current view of CLL as a chronic disease in which the host's microenvironment promotes leukemic cell growth and also controls the sequential acquisition and accumulation of genetic alterations. This view relies on the existence of a set of surface molecules, including CD38, which support proliferation and survival of B cells on their way to and after neoplastic transformation. The second decade of studies on CD38 in CLL will tell if the molecule is an effective target for antibody-mediated therapy in this currently incurable leukemia.",
author = "Fabio Malavasi and Silvia Deaglio and Rajendra Damle and Giovanna Cutrona and Manlio Ferrarini and Nicholas Chiorazzi",
year = "2011",
month = "9",
day = "29",
doi = "10.1182/blood-2011-06-275610",
language = "English",
volume = "118",
pages = "3470--3478",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - CD38 and chronic lymphocytic leukemia

T2 - A decade later

AU - Malavasi, Fabio

AU - Deaglio, Silvia

AU - Damle, Rajendra

AU - Cutrona, Giovanna

AU - Ferrarini, Manlio

AU - Chiorazzi, Nicholas

PY - 2011/9/29

Y1 - 2011/9/29

N2 - This review highlights a decade of investigations into the role of CD38 in CLL. CD38 is accepted as a dependable marker of unfavorable prognosis and as an indicator of activation and proliferation of cells when tested. Leukemic clones with higher numbers of CD38 + cells are more responsive to BCR signaling and are characterized by enhanced migration. In vitro activation through CD38 drives CLL proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2. Finally, CD38 is under a polymorphic transcriptional control after external signals. Consequently, CD38 appears to be a global molecular bridge to the environment, promoting survival/proliferation over apoptosis. Together, this evidence contributes to the current view of CLL as a chronic disease in which the host's microenvironment promotes leukemic cell growth and also controls the sequential acquisition and accumulation of genetic alterations. This view relies on the existence of a set of surface molecules, including CD38, which support proliferation and survival of B cells on their way to and after neoplastic transformation. The second decade of studies on CD38 in CLL will tell if the molecule is an effective target for antibody-mediated therapy in this currently incurable leukemia.

AB - This review highlights a decade of investigations into the role of CD38 in CLL. CD38 is accepted as a dependable marker of unfavorable prognosis and as an indicator of activation and proliferation of cells when tested. Leukemic clones with higher numbers of CD38 + cells are more responsive to BCR signaling and are characterized by enhanced migration. In vitro activation through CD38 drives CLL proliferation and chemotaxis via a signaling pathway that includes ZAP-70 and ERK1/2. Finally, CD38 is under a polymorphic transcriptional control after external signals. Consequently, CD38 appears to be a global molecular bridge to the environment, promoting survival/proliferation over apoptosis. Together, this evidence contributes to the current view of CLL as a chronic disease in which the host's microenvironment promotes leukemic cell growth and also controls the sequential acquisition and accumulation of genetic alterations. This view relies on the existence of a set of surface molecules, including CD38, which support proliferation and survival of B cells on their way to and after neoplastic transformation. The second decade of studies on CD38 in CLL will tell if the molecule is an effective target for antibody-mediated therapy in this currently incurable leukemia.

UR - http://www.scopus.com/inward/record.url?scp=80053350162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053350162&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-06-275610

DO - 10.1182/blood-2011-06-275610

M3 - Article

VL - 118

SP - 3470

EP - 3478

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -